AU2012212463B2 - Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses - Google Patents
Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses Download PDFInfo
- Publication number
- AU2012212463B2 AU2012212463B2 AU2012212463A AU2012212463A AU2012212463B2 AU 2012212463 B2 AU2012212463 B2 AU 2012212463B2 AU 2012212463 A AU2012212463 A AU 2012212463A AU 2012212463 A AU2012212463 A AU 2012212463A AU 2012212463 B2 AU2012212463 B2 AU 2012212463B2
- Authority
- AU
- Australia
- Prior art keywords
- mva
- seq
- region
- set out
- gene cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000028993 immune response Effects 0.000 title claims abstract description 16
- 241000712431 Influenza A virus Species 0.000 title claims abstract description 14
- 230000001939 inductive effect Effects 0.000 title claims description 7
- 239000013603 viral vector Substances 0.000 title abstract description 13
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims abstract description 113
- 108090000623 proteins and genes Proteins 0.000 claims description 94
- 241000700618 Vaccinia virus Species 0.000 claims description 57
- 101710154606 Hemagglutinin Proteins 0.000 claims description 55
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 55
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 55
- 101710176177 Protein A56 Proteins 0.000 claims description 55
- 239000000185 hemagglutinin Substances 0.000 claims description 50
- 108020001507 fusion proteins Proteins 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 241000700605 Viruses Species 0.000 claims description 41
- 102000037865 fusion proteins Human genes 0.000 claims description 41
- 208000037797 influenza A Diseases 0.000 claims description 37
- 238000012217 deletion Methods 0.000 claims description 32
- 230000037430 deletion Effects 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 239000013612 plasmid Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 241000287828 Gallus gallus Species 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 108091029795 Intergenic region Proteins 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 8
- 208000007089 vaccinia Diseases 0.000 claims description 8
- 101150118742 NP gene Proteins 0.000 claims description 7
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 7
- 108020004440 Thymidine kinase Proteins 0.000 claims description 7
- 241000271566 Aves Species 0.000 claims description 6
- 210000001161 mammalian embryo Anatomy 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 3
- 101710199771 Matrix protein 1 Proteins 0.000 claims description 2
- -1 HA2 amino acids Chemical class 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 206010072219 Mevalonic aciduria Diseases 0.000 description 84
- 108010061100 Nucleoproteins Proteins 0.000 description 40
- 102000011931 Nucleoproteins Human genes 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 28
- 229960005486 vaccine Drugs 0.000 description 28
- 206010022000 influenza Diseases 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 21
- 101710085035 RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 108700026244 Open Reading Frames Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000010276 construction Methods 0.000 description 8
- 241000712461 unidentified influenza virus Species 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 150000002333 glycines Chemical class 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 229960003971 influenza vaccine Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 101150082969 SELP gene Proteins 0.000 description 3
- 101150036293 Selenop gene Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000001932 seasonal effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 1
- 238000006037 Brook Silaketone rearrangement reaction Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940033324 influenza A vaccine Drugs 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016235002A AU2016235002B2 (en) | 2011-01-31 | 2016-09-30 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438024P | 2011-01-31 | 2011-01-31 | |
| US61/438,024 | 2011-01-31 | ||
| PCT/US2012/023085 WO2012106231A2 (en) | 2011-01-31 | 2012-01-30 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016235002A Division AU2016235002B2 (en) | 2011-01-31 | 2016-09-30 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012212463A1 AU2012212463A1 (en) | 2013-05-02 |
| AU2012212463B2 true AU2012212463B2 (en) | 2016-07-07 |
Family
ID=45561167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012212463A Active AU2012212463B2 (en) | 2011-01-31 | 2012-01-30 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses |
| AU2016235002A Active AU2016235002B2 (en) | 2011-01-31 | 2016-09-30 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016235002A Active AU2016235002B2 (en) | 2011-01-31 | 2016-09-30 | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9463237B2 (enExample) |
| EP (1) | EP2670430B1 (enExample) |
| JP (2) | JP6169494B2 (enExample) |
| CN (1) | CN103458922B (enExample) |
| AU (2) | AU2012212463B2 (enExample) |
| WO (1) | WO2012106231A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2670430B1 (en) * | 2011-01-31 | 2015-04-01 | Baxter International Inc | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
| US10434166B2 (en) * | 2013-03-15 | 2019-10-08 | University Of Maryland, College Park | Methods and compositions for in vivo immune stimulation and antigen production |
| US10286062B2 (en) | 2013-07-09 | 2019-05-14 | Texas Tech University System | Universal influenza vaccine |
| CA3003103A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| PL3402802T3 (pl) * | 2016-01-08 | 2023-06-05 | Geovax, Inc. | Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym |
| US10370416B2 (en) * | 2016-03-01 | 2019-08-06 | Texas Tech University System | Dual purpose universal influenza vaccine confers protective immunity against anthrax |
| KR102731582B1 (ko) | 2016-06-03 | 2024-11-15 | 사노피 파스퇴르 인코포레이티드 | 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형 |
| CN107841513B (zh) * | 2016-09-18 | 2023-04-14 | 中国科学院上海巴斯德研究所 | 基于M2e表位的广谱型流感疫苗 |
| US10925958B2 (en) | 2016-11-11 | 2021-02-23 | Modernatx, Inc. | Influenza vaccine |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| JP7382634B2 (ja) * | 2017-12-21 | 2023-11-17 | 株式会社グリーンバイオメッド | 交差免疫抗原ワクチン及びその調製方法 |
| CN109096376A (zh) * | 2018-09-20 | 2018-12-28 | 扬州大学 | 流感病毒ha多肽、klh偶联多肽及多克隆抗体的制备方法 |
| CN113004422B (zh) * | 2021-03-04 | 2023-01-20 | 辽宁成大生物股份有限公司 | 一种融合蛋白、含其的疫苗及其应用 |
| WO2023019274A1 (en) * | 2021-08-13 | 2023-02-16 | Purdue Research Foundation | Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010117786A1 (en) * | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| AT393277B (de) | 1990-01-04 | 1991-09-25 | Immuno Ag | Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen |
| MX2008009929A (es) * | 2006-02-02 | 2008-10-01 | Globeimmune Inc | Vacuna a base de levadura para inducir una respuesta inmune. |
| EP1820511A1 (en) * | 2006-02-20 | 2007-08-22 | Prolmmune Limited | MHC binding peptides and their uses |
| CA2673994A1 (en) * | 2006-12-29 | 2008-07-24 | Institut Pasteur Of Shanghai | Lentivirus pseudotyped with influenza hemagglutinin and methods of use |
| EP2134361A4 (en) * | 2007-03-26 | 2010-09-22 | Univ Massachusetts Medical | Compositions and methods for increasing immunogenicity of glycoprotein vaccines |
| US20110177122A1 (en) * | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
| US7998488B2 (en) | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
| CA2762044A1 (en) | 2009-05-18 | 2010-11-25 | Panacea Biotec Ltd | Universal influenza vaccine based on recombinant modified vaccinia ankara virus (mva) |
| EP2670430B1 (en) | 2011-01-31 | 2015-04-01 | Baxter International Inc | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
-
2012
- 2012-01-30 EP EP12702162.4A patent/EP2670430B1/en active Active
- 2012-01-30 AU AU2012212463A patent/AU2012212463B2/en active Active
- 2012-01-30 JP JP2013552568A patent/JP6169494B2/ja active Active
- 2012-01-30 WO PCT/US2012/023085 patent/WO2012106231A2/en not_active Ceased
- 2012-01-30 CN CN201280015880.9A patent/CN103458922B/zh active Active
- 2012-01-30 US US13/982,524 patent/US9463237B2/en active Active
-
2016
- 2016-09-30 AU AU2016235002A patent/AU2016235002B2/en active Active
- 2016-10-07 US US15/289,106 patent/US10329583B2/en active Active
-
2017
- 2017-06-28 JP JP2017126499A patent/JP6461244B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010117786A1 (en) * | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6169494B2 (ja) | 2017-07-26 |
| WO2012106231A3 (en) | 2012-09-20 |
| WO2012106231A2 (en) | 2012-08-09 |
| AU2016235002B2 (en) | 2018-08-09 |
| EP2670430B1 (en) | 2015-04-01 |
| US10329583B2 (en) | 2019-06-25 |
| US9463237B2 (en) | 2016-10-11 |
| EP2670430A2 (en) | 2013-12-11 |
| JP2017221195A (ja) | 2017-12-21 |
| US20170121735A1 (en) | 2017-05-04 |
| JP6461244B2 (ja) | 2019-01-30 |
| CN103458922B (zh) | 2017-10-03 |
| CN103458922A (zh) | 2013-12-18 |
| US20140050759A1 (en) | 2014-02-20 |
| JP2014506785A (ja) | 2014-03-20 |
| AU2012212463A1 (en) | 2013-05-02 |
| AU2016235002A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012212463B2 (en) | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses | |
| US20240075125A1 (en) | Expression systems | |
| ES2929942T3 (es) | Vacunas contra el virus de la gripe y sus usos | |
| US20110159031A1 (en) | Vaccine to Influenza A Virus | |
| Altstein et al. | Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses | |
| JP2012527232A (ja) | 遺伝子組換え改変ワクシニアアンカラウイルス（ｍｖａ）ベースのインフルエンザ万能ワクチン | |
| EP3103474A1 (en) | Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses | |
| Stropkovská et al. | Trends in development of the influenza vaccine with broader cross-protection | |
| HK1216392B (en) | Influenza virus vaccines and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: NANOTHERAPEUTICS, INC. Free format text: FORMER APPLICANT(S): BAXTER HEALTHCARE SA; BAXTER INTERNATIONAL INC. |
|
| FGA | Letters patent sealed or granted (standard patent) |